http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004224989-A1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 |
filingDate | 2004-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_936c424cb4b043160d5ae6fa92be6585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e2865addfaa2b982970a2e8f9966a75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67560c482293eda7d3261c982a09360f |
publicationDate | 2004-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2004224989-A1 |
titleOfInvention | S-lansoprazole compositions and methods |
abstract | Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also-useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H + release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome. |
priorityDate | 1999-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.